J. Vanderdonk et al., PATIENT PARTICIPATION IN CLINICAL DECISION-MAKING FOR TREATMENT OF T3LARYNGEAL-CANCER - A COMPARISON OF STATE AND PROCESS UTILITIES, Journal of clinical oncology, 13(9), 1995, pp. 2369-2378
Purpose: To study the use of two different approaches, and feasibility
of four commonly used utility assessment methods to assess preference
s for treatment of TS-laryngeal cancer by surgery or radiation therapy
(RT), Methods: Utility assessment methods, namely, time trade-off (TT
O), standard reference gamble (SRG), rating scale (RS), and direct com
parison (DC), were used to assess utilities in two groups of former ca
ncer patients (n = 10 for both), a group of clinicians (n = 9), and a
group from the general population (n = 10). For the treatment modaliti
es, ie, surgery and RT, two types of scenarios were developed and used
: the state scenario, which describes a stable health state after trea
tment, and the process scenario, which describes a dynamic process, Fi
rst, utilities were assessed based on state scenarios, Next, responden
ts were thoroughly informed and educated with respect to the relevant
aspects of both treatment modalities. Subsequently, utilities were aga
in assessed, but now based on the process scenarios, The outcome of ea
ch approach wets calculated and expressed in a quality-adjusted life-e
xpectancy (QALE) score for each treatment modality, and the treatment
with the highest outcome was said to be the preferred treatment modali
ty. Results: In general, a higher QALE score for each treatment modali
ty was found for clinicians and for the general population as compared
with the former-cancer-patient groups. When the outcome of both appro
aches was compared on an individual level dependent on the utility ass
essment method, 32% to 43% of respondents showed an inconsistent treat
ment preference, Conclusion: The approach to assess utilities and the
extent to which respondents are informed about treatment modalities ha
ve a major effect on individual treatment preferences. (C) 1995 by Ame
rican Society of Clinical Oncology.